Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Tipranavir and BILR 355 in Healthy Volunteers
NCT02257021Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2005
- Primary completion
- May 2005
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of BILR 355 in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve at steady state over one dosing interval (12 hours) up to 18 days and Maximum measured concentration at steady state up to 18 days. Started Feb 2005; status: completed.
02
Drugs
BILR 355
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02257021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02257021.